Overview
A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.
Major marketed drugs for HR+/HER2- breast cancer are discussed, including the cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors. Key late-phase pipeline drugs are also covered, with a focus on Novartis’s alpelisib.
A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.
Major marketed drugs for HR+/HER2- breast cancer are discussed, including the cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors. Key late-phase pipeline drugs are also covered, with a focus on Novartis’s alpelisib.
